Clinical Trial

 

STRO-001-BM1

 

Sutro is currently advancing two wholly owned clinical-stage programs designed to provide patient benefit across multiple areas of unmet need.

STRO-001-BM1 is a CD74 Targeting antibody drug conjugate (ADC) for the potential treatment of multiple myeloma and NHL.

  • STRO-001-BCM1 is an ongoing first-in-human, phase 1, open-label, multicenter, dose escalation study evaluating the safety, tolerability and preliminary anti-tumor activity of STRO-001-BM1 in adults with B-cell malignancies (NHL and multiple myeloma).

STRO-001-BM1 is a novel homogeneous ADC using precisely positioned non-natural amino acids.

  • STRO-001-BM1 targets the tumor cell carrying two cytotoxins, these are non-cleavable maytansinoid linker-warheads (DAR=2) that are stable in circulation
  • The active warhead is internalized by the tumor cells, efficiently killing them while minimizing damage to surrounding healthy cells.

STRO–001-BM1 has received Orphan Drug designation for Multiple Myeloma patients.

For more information about this trial, visit www.clinicaltrials.gov

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080
Phone: 650-881-6500
Fax: 650-553-9659

Google Map

Contact Us

General Inquires: general@sutrobio.com
Business Inquires: busdev@sutrobio.com
Investor Relations Inquires: IR@sutrobio.com
Careers:
jobs@sutrobio.com

Sutro Biopharma, Inc.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.